In the present study, we describe a novel agonist [N6-(4-hydroxybenzyl)adenine riboside (designated T1-11)] of the A2AR that also inhibits the adenosine transporter, and which may be used to treat HD without evident side effects because of its moderate affinity to its target molecules. The gene discussed is ADORA2A; the disease is Huntington disease.